公开(公告)号：US20090239237A1

公开(公告)日：2009-09-24

申请号：US12474794

申请日：2009-05-29

申请人： Detlef KOZIAN ,  Stefan SCHAEFER ,  Bernward SCHOELKENS ,  Karl-Ernst SIEGLER ,  Jean-Francois DELEUZE ,  Sylvain RICARD ,  Sandrine MACE

发明人： Detlef KOZIAN ,  Stefan SCHAEFER ,  Bernward SCHOELKENS ,  Karl-Ernst SIEGLER ,  Jean-Francois DELEUZE ,  Sylvain RICARD ,  Sandrine MACE

IPC分类号： C12Q1/68

CPC分类号： G01N33/6893 ,  Y10S436/811

摘要： The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.

摘要翻译： 本发明涉及一种鉴定血栓形成疾病风险的方法，包括但不限于心房颤动，中风，延迟性间歇性神经功能缺损（PRIND），短暂性缺血发作（TIA），动脉粥样硬化性脑血管病（CVD）和/或冠状动脉疾病 心脏病以及用于选择具有血栓形成障碍风险的患者的方法，用于鉴定用于治疗或预防血栓形成疾病的药物的方法以及用于制备药物的方法和诊断方法 采用TAFI-Ile347多态性。

公开(公告)号：US20110223628A1

公开(公告)日：2011-09-15

申请号：US13109111

申请日：2011-05-17

申请人： Detlef KOZIAN ,  Stefan SCHAEFER ,  Bernward SCHOELKENS ,  Karl-Ernst SIEGLER ,  Jean-Francois DELEUZE ,  Sylvain RICARD ,  Sandrine MACE

发明人： Detlef KOZIAN ,  Stefan SCHAEFER ,  Bernward SCHOELKENS ,  Karl-Ernst SIEGLER ,  Jean-Francois DELEUZE ,  Sylvain RICARD ,  Sandrine MACE

IPC分类号： C12Q1/37

CPC分类号： G01N33/6893 ,  Y10S436/811

摘要： The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.

摘要翻译： 本发明涉及一种鉴定血栓形成疾病风险的方法，包括但不限于心房颤动，中风，延迟性间歇性神经功能缺损（PRIND），短暂性缺血发作（TIA），动脉粥样硬化性脑血管病（CVD）和/或冠状动脉疾病 心脏病以及用于选择具有血栓形成障碍风险的患者的方法，用于鉴定用于治疗或预防血栓形成疾病的药物的方法以及用于制备药物的方法和诊断方法 采用TAFI-Ile347多态性。

公开(公告)号：US20140106366A1

公开(公告)日：2014-04-17

申请号：US14017854

申请日：2013-09-04

申请人： Thomas LICHER ,  Hans-Willi JANSEN ,  Ursula SCHINDLER ,  Stefan SCHAEFER

发明人： Thomas LICHER ,  Hans-Willi JANSEN ,  Ursula SCHINDLER ,  Stefan SCHAEFER

IPC分类号： G01N33/68

CPC分类号： G01N33/6872 ,  G01N33/5008

摘要： The present invention relates to methods for determining the efficiency of an ion channel ligand comprising (a) contacting a cell expressing the ion channel with (i) plasma of an animal and (ii) the ion channel ligand and (b) determining the effect of the ion channel ligand on the cell.

摘要翻译： 本发明涉及用于确定离子通道配体的效率的方法，其包括（a）使表达离子通道的细胞与（i）动物血浆和（ii）离子通道配体）和（b）确定 细胞上的离子通道配体。